Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
2.470
-0.020 (-0.80%)
Nov 21, 2024, 12:25 PM EST - Market open
Palisade Bio Revenue
In the year 2023, Palisade Bio had annual revenue of $250.00K.
Revenue (ttm)
$250.00K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
3.28M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionPALI News
- 4 hours ago - Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC) - GlobeNewsWire
- 9 days ago - Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108 - GlobeNewsWire
- 21 days ago - Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewsWire
- 6 weeks ago - Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) - GlobeNewsWire
- 3 months ago - Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis - GlobeNewsWire
- 4 months ago - Palisade Bio Participates in Virtual Investor “What this Means” Segment - GlobeNewsWire
- 4 months ago - Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108 - GlobeNewsWire